EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease

Itaru Iwama iD, Masashi Yoshida, Ayako Miyazawa, Tomoko Hara, Ryusuke Nambu iD

Inflammatory Bowel Diseases · 03.07.2024 · 30 (7) · 1220-1222

DOI: 10.1093/ibd/izae078 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 08.04.2024. Verfasst von Itaru Iwama und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Remission Induction, Ustekinumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lay Summary We observed efficacy and safety of ustekinumab in very early-onset inflammatory bowel disease, which has not been previously reported. Clinical remission at 52% was 75%, often persisting beyond 2 years. Further studies including larger numbers of cases are needed to confirm this observation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesRemission InductionUstekinumabHumansAge of OnsetTreatment Outcome

Stichwörter der Autor:innen

steroid-free clinical remissionustekinumabvery early-onset inflammatory bowel disease

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.

ORCID-Profile: Itaru Iwama, Ryusuke Nambu

Zitieren

APA

Iwama, I., Yoshida, M., Miyazawa, A., Hara, T., & Nambu, R. (2024). Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 30(7), 1220-1222. https://doi.org/10.1093/ibd/izae078

Vancouver

Iwama I, Yoshida M, Miyazawa A, Hara T, Nambu R. Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024;30(7):1220-1222. doi:10.1093/ibd/izae078

BibTeX
@article{Iwama2024,
  author = {Iwama, Itaru and Yoshida, Masashi and Miyazawa, Ayako and Hara, Tomoko and Nambu, Ryusuke},
  title = {Ustekinumab Offers Long-Term Clinical Remission With Safety in Very Early-Onset Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {7},
  pages = {1220--1222},
  doi = {10.1093/ibd/izae078}
}
Kostenlos starten →